| Literature DB >> 25898186 |
Xinlai Cheng1, Eleni Dimou1, Hamed Alborzinia1, Frank Wenke2, Axel Göhring2, Stefanie Reuter2, Nancy Mah3, Heiko Fuchs4, Miguel A Andrade-Navarro3, James Adjaye4, Sheraz Gul5, Christoph Harms6, Jochen Utikal7, Edda Klipp8, Ralf Mrowka2, Stefan Wölfl1.
Abstract
Reprogramming somatic cells into induced-pluripotent cells (iPSCs) provides new access to all somatic cell types for clinical application without any ethical controversy arising from the use of embryonic stem cells (ESCs). Established protocols for iPSCs generation based on viral transduction with defined factors are limited by low efficiency and the risk of genetic abnormality. Several small molecules have been reported as replacements for defined transcriptional factors, but a chemical able to replace Oct3/4 allowing the generation of human iPSCs is still unavailable. Using a cell-based High Throughput Screening (HTS) campaign, we identified that 2-[4-[(4-methoxyphenyl)methoxy]phenyl]acetonitrile (1), termed O4I1, enhanced Oct3/4 expression. Structural verification and modification by chemical synthesis showed that O4I1 and its derivatives not only promoted expression and stabilization of Oct3/4 but also enhanced its transcriptional activity in diverse human somatic cells, implying the possible benefit from using this class of compounds in regenerative medicine.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25898186 DOI: 10.1021/acs.jmedchem.5b00144
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446